Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction

International Journal of Molecular Medicine

Volumn 18, Issue 5, 2006, Pages 909-915

  Hayashi, Sachiko ^a   Hatashita, Masanori ^b   Matsumoto, Hideki ^a   Shioura, Hiroki ^a   Kitai, Ryuhei ^a   Kano, Eiichi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b Wakasawan Energy Research Center   (Japan)

Author keywords

Amrubicin; Apoptosis; Enhancement; Human lung adenocarcinoma A549 cells; Necrosis; Radiosensitivity; Topoisomerase II; X rays

Indexed keywords

AMRUBICIN; AMRUBICINOL; ANTHRACYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); RADIOSENSITIZING AGENT;

ADENOCARCINOMA; APOPTOSIS; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; KINETICS; LUNG TUMOR; NECROSIS; RADIATION DOSE; TUMOR CELL LINE; X RAY;

ADENOCARCINOMA; ANTHRACYCLINES; APOPTOSIS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; HUMANS; KINETICS; LUNG NEOPLASMS; NECROSIS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; X-RAYS;

EID: 34248359723     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.18.5.909     Document Type: Article

References (56)

1. Noguchi T, Ichii S, Morisada S, Yamaoka T and Yanagi Y: In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 89: 1055-1060, 1998.
2. Noguchi T, Ichii S, Morisada S, Yamaoka T and Yanagi Y: Tumor-selective distribution of an active metabolite of the 9- aminoanthracycline amrubicin. Jpn J Cancer Res 89: 1061-1066, 1998. (Pubitemid 28544783)
3. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T and Yamaoka T: A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II - DNA complex. Jpn J Cancer Res 89: 1229-1238, 1998.
4. Yamauchi S, Kudoh S, Kimura T, Hirata K and Yoshikawa J: Additive effects of amrubicin with cisplatin on human lung cancer cell lines. Osaka City Med J 48: 69-76, 2002.
5. Ogawa M: Novel anticancer drugs in Japan. J Cancer Res Clin Oncol 125: 134-140, 1999.
6. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T and Yanagi Y: Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89: 1067-1073, 1998.
7. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y and Fukui M: Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 80: 69-76, 1989.
8. Evans HH, Ricanati M, Horng MF and Mencl J: Relationship between topoisomerase II and radiosensitivity in mouse L5178Y lymphoma strains. Mutat Res 217: 53-63, 1989. (Pubitemid 19022544)
9. Coco-Martin JM, Smeets MF, Poggensee M, et al: Use of fluorescence in situ hybridization to measure chromosome aberrations as a predictor of radiosensitivity in human tumour cells. Int J Radiat Biol 66: 297-307, 1994.
10. Guo WF, Lin RX, Huang J, et al: Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis. Radiat Res 164: 27-35, 2005. (Pubitemid 40885227)
11. Harari PM, Fuller DJ, Carper SW, Croghan MK, Meyskens FL Jr, Shimm DS and Gerner EW: Polyamine biosynthesis inhibitors combined with systemic hyperthermia in cancer therapy. Int J Radiat Oncol Biol Phys 19: 89-96, 1990. (Pubitemid 20239790)
12. Armour EP, McEachern D, Wang Z, Corry PM and Martinez A: Sensitivity of human cells to mild hyperthermia. Cancer Res 53: 2740-2744, 1993. (Pubitemid 23180508)
13. Hayashi S, Hatashita M, Matsumoto H, Jin ZH, Shioura H and Kano E: Modification of thermosensitivity by amrubicin or amrubicinol in human lung adenocarcinoma A549 cells and the kinetics of apoptosis and necrosis induction. Int J Mol Med 16: 381-387, 2005.
14. Valenzuela DM and Groffen J: Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras oncogene. Nucleic Acids Res 14: 843-852, 1986.
15. Lehman TA, Bennett WP, Metcalf RA, et al: p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 51: 4090-4096, 1991.
16. Noble JR, Willetts KE, Mercer WE and Reddel RR: Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. Exp Cell Res 203: 297-304, 1992.
17. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347, 1991.
18. Shaw P, Bovey R, Tardy S, et al: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89: 4495-4499, 1992.
19. Martinez J, Georgoff I, Martinez J and Levine AJ: Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 5: 151-159, 1991.
20. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495, 1992.
21. Sionov RV and Haupt Y: The cellular response to p53: the decision between life and death. Oncogene 18: 6145-6157, 1999.
22. Vousden KH: p53: death star. Cell 103: 691-694, 2000.
23. Hayashi S, Kano E, Tsuji K, Furukawa-Furuya M, Yoshikawa S, Hatashita M, Matsumoto H, Jin ZH, Ohtsubo T and Kitai R: Modification of thermosensitivity and chemosensitivity induced by combined treatments with hyperthermia and adriamycin. Int J Mol Med 8: 417-422, 2001.
24. Yonish-Rouach E, Grunwald D, Wilder S, Kimchi A, May E, Lawrence JJ, May P and Oren M: p53-mediated cell death: Relationship to cell cycle control. Mol Cell Biol 13: 1415-1423, 1993.
25. Hayashi S, Kano E, Matsumoto H, Hatashita M, Ohtsubo T, Nishida T, Shioura H and Kitai R: Thermosensitivity, incidence of apoptosis and accumulations of hsp72 and p53 proteins of murine L cells in wild type status of p53 gene. J Exp Clin Cancer Res 18: 181-189, 1999.
26. Ogawa Y, Nishioka A, Inomata T, et al: Ionizing radiation-induced apoptosis in human lymphoma cell lines differing in p53 status. Int J Mol Med 5: 139-143, 2000.
27. Lowy DR and Willumsen BM: Function and regulation of ras. Annu Rev Biochem 62: 851-891, 1993.
28. Kaziro Y, Itoh H, Kozasa T, Nakafuku M and Satoh T: Structure and function of signal-transducing GTP-binding proteins. Annu Rev Biochem 60: 349-400, 1991.
29. McBride OW, Swan DC, Tronick SR, Gol R, Klimanis D, Moore DE and Aaronson SA: Regional chromosomal localization of N-ras, K-ras-1, K-ras-2 and myb oncogenes in human cells. Nucleic Acids Res 11: 8221-8236, 1983.
30. Elkind MM and Sutton H: X-ray damage and recovery in mammalian cells in culture. Nature 184: 1293-1295, 1959.
31. Elkind MM, Sutton-Gilbert H, Moses WB, Alescio T and Swain RW: Radiation response of mammalian cells grown in culture. V. Temperature dependence of the repair of X-ray damage in surviving cells (aerobic and hypoxic). Radiat Res 25: 359-376, 1965.
32. Marchese MJ, Zaider M and Hall EJ: Dose-rate effects in normal and malignant cells of human origin. Br J Radiol 60: 573-576, 1987. (Pubitemid 17099283)
33. Matthews JH, Meeker BE and Chapman JD: Response of human tumor cell lines in vitro to fractionated irradiation. Int J Radiat Oncol Biol Phys 16: 133-138, 1989.
34. Cummings J and Smyth JF: DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 4: 533-543, 1993. (Pubitemid 23257550)
35. Tewey KM, Rowe TC, Yang L, Halligan BD and Liu LF: Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466-468, 1984. (Pubitemid 14012819)
36. Hill BT, Whelan RD, Hosking LK, et al: A lack of detectable modification of topoisomerase II activity in a series of human tumor cell lines expressing only low levels of etoposide resistance. Int J Cancer 47: 899-902, 1991.
37. Lock RB and Hill BT: Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines. Int J Cancer 42: 373-381, 1988.
38. Kerr JF, Wyllie AH and Currie AR: Apoptosis; a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
39. Khodarev NN, Sokolova IA and Vaughan AT: Mechanisms of induction of apoptotic DNA fragmentation. Int J Radiat Biol 73: 455-467, 1998. (Pubitemid 28261228)
40. Allan DJ and Harmon BV: The morphologic categorization of cell death induced by mild hyperthermia and comparison with death induced by ionizing radiation and cytotoxic drugs. Scanning Electron Microsc: 1121-1133, 1986.
41. Cho KS, Lee EH, Choi JS and Joo CK: Reactive oxygen species-induced apoptosis and necrosis in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci 40: 911-919, 1999.
42. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H and Parks WP: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423, 1973.
43. Lieber M, Smith B, Szakal A, Nelson-Rees W and Todaro G: A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 17: 62-70, 1976.
44. Leite M, Quinta-Costa M, Leite PS and Guimaraes JE: Critical evaluation of techniques to detect and measure cell death-study in a model of UV radiation of the leukaemic cell line HL60. Anal Cell Pathol 19: 139-151, 1999.
45. Wang JC: Recent studies of DNA topoisomerases. Biochim Biophys Acta 909: 1-9, 1987.
46. Kelly TJ: SV40 DNA replication. J Biol Chem 263: 17889-17892, 1988.
47. Nelson EM, Tewey KM and Liu LF: Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9- acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA 81: 1361-1365, 1984.
48. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
49. Kampinga HH: Hyperthermia, thermotolerance and topoisomerase II inhibitors. Br J Cancer 72: 333-338, 1995.
50. Ohtsubo T, Kano E, Ueda K, Matsumoto H, Saito T, Hayashi S, Hatashita M, Jin Z and Saito H: Enhancement of heat-induced heat shock protein (hsp)72 accumulation by doxorubicin (Dox) in vitro. Cancer Lett 159: 49-55, 2000.
51. Ohtsubo T, Saito H, Matsumoto H, Hayashi S, Shioura H, Kitai R, Saito T and Kano E: In vitro effects of hyperthermia combined with cisplatin or peplomycin on the human maxillary carcinoma cell line IMC-2. Int J Hyperthermia 13: 59-67, 1997.
52. Shioura H, Hayashi S, Matsumoto H, Kitai R, Ohtsubo T, Nishida T, Zhang SW, Yoshida M, Ishii Y and Kano E: The effects of combined treatments with low hyperthermia and bleomycin on survivals of murine L cells. J Exp Clin Cancer Res 16: 147-152, 1997.
53. Matsumoto H, Hayashi S, Shioura H, Ohtsubo T, Nishida T, Kitai R, Ohnishi T and Kano E: Suppression of heat-induced p53 accumulation and activation by CDDP or X-rays in human glioblastoma cells. Int J Oncol 13: 741-747, 1998.
54. Arcamone F, Franceschi G, Penco S and Selva A: Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic. Tetrahedron Lett 13: 1007-1010, 1969.
55. Gensler WJ and Gatsonis CD: The podophyllotoxin-picropodophyllin equilibrium. J Org Chem 31: 3224-3227, 1966.
56. Ryan JJ, Danish R, Gottlieb CA and Clarke MF: Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol Cell Biol 13: 711-719, 1993.